Skip to main content
ABIONYX Pharma logo

ABIONYX Pharma — Investor Relations & Filings

Ticker · ABNX ISIN · FR0012616852 LEI · 969500785J7VIC5YPC96 PA Manufacturing
Open in API
Filings indexed 657 across all filing types
Latest filing 2026-05-07 Regulatory Filings
Country FR France
Listing PA ABNX

About ABIONYX Pharma

https://abionyx.com/en/

ABIONYX Pharma is a new-generation biotechnology company that develops innovative therapies for indications with no effective or existing treatments. The company leverages extensive expertise in lipid metabolism and is a leader in recombinant apolipoprotein A-I (apoA-I), the primary protein of High-Density Lipoprotein (HDL). Its core technology platform utilizes apoA-I to create novel biotherapies and HDL vectors for targeted drug delivery. Key therapeutic areas of focus include critical illnesses such as sepsis, as well as renal and ophthalmological diseases. The company's strategy involves an integrated approach, combining biotherapy with diagnostics to address complex medical conditions with high unmet needs.

Recent filings

Filing Released Lang Actions
Informations privilégiées / Autres communiqués
Regulatory Filings
2026-05-07 French
Inside Information / Other news releases
Regulatory Filings
2026-05-07 English
Inside Information / Other news releases
Regulatory Filings Classification · 75% confidence The document is a mandatory monthly statement of total voting rights and shares under French Commercial Code and AMF regulations. It does not announce meeting results (so not DVA), nor is it reporting a capital change or threshold crossing by a major shareholder. It is a routine regulatory disclosure that does not fit any more specific category, so it falls under the fallback “Regulatory Filings” category.
2026-04-08 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 85% confidence The document is a French press release disclosing the total number of shares and voting rights, as required under AMF rules. It is not announcing a capital transaction (no new share issue or stock split), nor reporting meeting vote outcomes, nor publishing a full financial report. It is a general regulatory announcement that does not fit any more specific category.
2026-04-08 French
Inside Information / Other news releases
Regulatory Filings Classification · 80% confidence The document is a corporate press release announcing a technological and industrial breakthrough in synthetic sphingomyelin production by ABIONYX Pharma. It does not present financial results, regulatory filings such as an annual or quarterly report, management changes, capital transactions, or dividend notices. It is not an investor presentation or call transcript but rather a general corporate news announcement. It therefore falls into the fallback “Regulatory Filings” category for miscellaneous corporate announcements.
2026-03-27 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 85% confidence The document is a corporate press release (“Communiqué de presse”) announcing a scientific and industrial breakthrough in the production of the biomédicament CER-001. It contains no financial results, no shareholder meeting materials, no regulatory filing references (e.g., annual or interim report), no dividend or capital transaction details, and no management changes. It is not a structured investor presentation or detailed financial report but rather a general business announcement. Within the provided classification schema, such general corporate announcements that do not fit a more specific category should be classified as a Regulatory Filing (RNS) as a fallback category.
2026-03-27 French

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.